FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044035331> ?p ?o ?g. }

• W2044035331 endingPage "34" @default.
• W2044035331 startingPage "30" @default.
• W2044035331 abstract "BACKGROUND Recombinant interferon-α (IFN) augments the cytotoxicity of both 5-fluorouracil (5-FU) and cisplatin in vitro. A Phase II study of 5-FU and IFN resulted in response rates of 25–27% in patients with metastatic esophageal carcinoma. METHODS A Phase II trial was initiated to determine the clinical utility of a three-drug combination (FIP) in patients with regionally advanced or metastatic esophageal carcinoma. Eligibility included biopsy-proven Stage III or IV squamous cell carcinoma or adenocarcinoma of the esophagus with no prior chemotherapy, adequate performance status, nutritional status, bone marrow, hepatic and renal function, and signed informed consent. Patients were treated in the exact sequence of IFN;nqcisplatin;nq5-FU. Patients received 5-FU, 750 mg/m2/day for 5 days followed by weekly bolus therapy at the same dose; cisplatin, 100 mg/m2 on Day 1, followed by weekly therapy, 25 mg/m2 over the course of 1 hour; and IFN, 10 MU subcutaneously 3 times/week beginning on Day 1. All patients received sargramostim (granulocyte-macrophage colony-stimulating factor, Escherichia coli-derived), 5 μg/kg subcutaneously 5 times/week. No patients received radiotherapy. RESULTS Twenty-four patients were enrolled; 23 were eligible, and 1 was excluded on pathology review (patient was found to have a leiomyoblastoma). The demographics of the population were: median age, 63 years (range, 43–73 years); 18 male patients; squamous cell carcinoma: adenocarcinoma ratio, 22:1; and Stage III:IV ratio, 10:13. Grade 3–4 National Cancer Institute Common Toxicity Criteria toxicities included: leukopenia (13), thrombocytopenia (14), and infection (9). Grade 3 diarrhea, mucositis, and vomiting occurred in 6 patients, 4 patients, and 1 patient, respectively. There were two instances of sudden death, likely related to tumor progression. Major responses occurred in 15 of 23 patients (65%; 95% confidence interval, 43%, 85%) (1 complete response, 14 partial responses). The median survival was 8.6 months; with a median follow-up of 26 months, estimated 30-month survival was 31%. CONCLUSIONS This regimen, although moderately toxic, has substantial activity in metastatic and regionally advanced squamous cell carcinoma of the esophagus. Further investigations should be conducted to determine the role of IFN in the treatment of esophageal carcinoma. Cancer 1996;78:30-4." @default.
• W2044035331 created "2016-06-24" @default.
• W2044035331 creator A5032770951 @default.
• W2044035331 creator A5036322157 @default.
• W2044035331 creator A5049849218 @default.
• W2044035331 creator A5053851809 @default.
• W2044035331 creator A5056126655 @default.
• W2044035331 creator A5071579916 @default.
• W2044035331 creator A5079960935 @default.
• W2044035331 creator A5089619585 @default.
• W2044035331 date "1996-07-01" @default.
• W2044035331 modified "2023-10-16" @default.
• W2044035331 title "Phase II clinical trial with 5-fluorouracil, recombinant interferon-α-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus" @default.
• W2044035331 cites W1947407197 @default.
• W2044035331 cites W1972770199 @default.
• W2044035331 cites W1994865959 @default.
• W2044035331 cites W2007085333 @default.
• W2044035331 cites W2007220590 @default.
• W2044035331 cites W2050229940 @default.
• W2044035331 cites W2051784631 @default.
• W2044035331 cites W2061112867 @default.
• W2044035331 cites W2076668534 @default.
• W2044035331 cites W2085762166 @default.
• W2044035331 cites W2204058214 @default.
• W2044035331 doi "https://doi.org/10.1002/(sici)1097-0142(19960701)78:1<30::aid-cncr6>3.0.co;2-l" @default.
• W2044035331 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8646722" @default.
• W2044035331 hasPublicationYear "1996" @default.
• W2044035331 type Work @default.
• W2044035331 sameAs 2044035331 @default.
• W2044035331 citedByCount "25" @default.
• W2044035331 countsByYear W20440353312014 @default.
• W2044035331 crossrefType "journal-article" @default.
• W2044035331 hasAuthorship W2044035331A5032770951 @default.
• W2044035331 hasAuthorship W2044035331A5036322157 @default.
• W2044035331 hasAuthorship W2044035331A5049849218 @default.
• W2044035331 hasAuthorship W2044035331A5053851809 @default.
• W2044035331 hasAuthorship W2044035331A5056126655 @default.
• W2044035331 hasAuthorship W2044035331A5071579916 @default.
• W2044035331 hasAuthorship W2044035331A5079960935 @default.
• W2044035331 hasAuthorship W2044035331A5089619585 @default.
• W2044035331 hasBestOaLocation W20440353311 @default.
• W2044035331 hasConcept C126322002 @default.
• W2044035331 hasConcept C141071460 @default.
• W2044035331 hasConcept C143998085 @default.
• W2044035331 hasConcept C2776694085 @default.
• W2044035331 hasConcept C2776907518 @default.
• W2044035331 hasConcept C2777546739 @default.
• W2044035331 hasConcept C2780456651 @default.
• W2044035331 hasConcept C2780873365 @default.
• W2044035331 hasConcept C2908647359 @default.
• W2044035331 hasConcept C31760486 @default.
• W2044035331 hasConcept C71924100 @default.
• W2044035331 hasConcept C90924648 @default.
• W2044035331 hasConcept C99454951 @default.
• W2044035331 hasConceptScore W2044035331C126322002 @default.
• W2044035331 hasConceptScore W2044035331C141071460 @default.
• W2044035331 hasConceptScore W2044035331C143998085 @default.
• W2044035331 hasConceptScore W2044035331C2776694085 @default.
• W2044035331 hasConceptScore W2044035331C2776907518 @default.
• W2044035331 hasConceptScore W2044035331C2777546739 @default.
• W2044035331 hasConceptScore W2044035331C2780456651 @default.
• W2044035331 hasConceptScore W2044035331C2780873365 @default.
• W2044035331 hasConceptScore W2044035331C2908647359 @default.
• W2044035331 hasConceptScore W2044035331C31760486 @default.
• W2044035331 hasConceptScore W2044035331C71924100 @default.
• W2044035331 hasConceptScore W2044035331C90924648 @default.
• W2044035331 hasConceptScore W2044035331C99454951 @default.
• W2044035331 hasIssue "1" @default.
• W2044035331 hasLocation W20440353311 @default.
• W2044035331 hasLocation W20440353312 @default.
• W2044035331 hasOpenAccess W2044035331 @default.
• W2044035331 hasPrimaryLocation W20440353311 @default.
• W2044035331 hasRelatedWork W147607596 @default.
• W2044035331 hasRelatedWork W1766112618 @default.
• W2044035331 hasRelatedWork W1967055341 @default.
• W2044035331 hasRelatedWork W1994410190 @default.
• W2044035331 hasRelatedWork W2027871150 @default.
• W2044035331 hasRelatedWork W2238151675 @default.
• W2044035331 hasRelatedWork W2240603099 @default.
• W2044035331 hasRelatedWork W2285738680 @default.
• W2044035331 hasRelatedWork W4229782854 @default.
• W2044035331 hasRelatedWork W1980133017 @default.
• W2044035331 hasVolume "78" @default.
• W2044035331 isParatext "false" @default.
• W2044035331 isRetracted "false" @default.
• W2044035331 magId "2044035331" @default.
• W2044035331 workType "article" @default.